Brain-derived neurotrophic factor

BioTRUST Nutrition® Launches Eternal Mind® Featuring Nutricog® as Groundbreaking Dietary Supplement for Cognitive Support

Retrieved on: 
Tuesday, March 26, 2024
Function (mathematics), Gallic acid, Attention, Brain, Ellagic acid, Longevity, Growth, Prevalence, Learning, BDNF, Science, Clinical, Memory, Disease, Name, Eternal, Ageing, Brain-derived neurotrophic factor, Marketing, Homocysteine, PLT, Food, Dietary supplement

MORRISTOWN, N.J., March 26, 2024 /PRNewswire/ -- PLT Health Solutions, Inc. announced BioTRUST Nutrition® LLC, a leading eCommerce-based nutrition brand with a portfolio of high-quality, science-backed products focused on healthy aging and improving healthspan, has introduced a new product targeted at providing brain longevity and cognitive support called Eternal Mind®. The new product features PLT's Nutricog® Cognitive Performance Complex, an ingredient that has been clinically demonstrated to provide significant improvements across multiple cognitive domains, including learning, memory, attention, focus, and executive function, where increases in cognitive speed were seen concurrently with improvements in accuracy while multitasking. In addition, clinical science showed that Nutricog doubled levels brain-derived neurotrophic factor (BDNF), a neuroprotein involved in the brain's ability to adapt to new information.

Key Points: 
  • Eternal Mind is available direct-to-consumer from the BioTRUST Nutrition website ( www.biotrust.com ) and via Amazon.
  • "Brain and cognitive health are a significant concern for many Americans, especially as we age.
  • However, navigating the cognitive supplement market can be challenging due to the prevalence of expensive products with ambiguous 'proprietary blends' and vague claims," Chris Marschall said.
  • According to BioTRUST®, Eternal Mind is backed by the latest science in brain health.

Pharmactive's Saffron Extract improves Resilience to Occasional Stress

Retrieved on: 
Wednesday, January 24, 2024
DSM-IV codes, Hypothalamus, Arginine, Iterative method, Pituitary gland, Research, Overalls, Manager, Food, Health, Brain-derived neurotrophic factor, HPA, Hormone, Survival, Communication, History, Nutrient, Anxiety, Pandemic, Human, Gland, Doctor of Philosophy, Rat, Anhedonia, ACTH, Adrenocorticotropic hormone, CRF, Brain, Motivation, Glucocorticoid, BDNF, Depression, Growth

MADRID, Jan. 24, 2024 /PRNewswire/ -- A new in vitro study sheds light to the stress relief effect of saffron (Crocus sativus L). The research highlights the ability of affron®, a standardized extract of saffron developed by Pharmactive Biotech Products to enhance resilience to occasional stress.

Key Points: 
  • The research highlights the ability of affron®, a standardized extract of saffron developed by Pharmactive Biotech Products to enhance resilience to occasional stress.
  • Results demonstrated significant improvements following repeated oral administration of the extract in stress model animal subjects.
  • The HPA axis is a vital brain signaling system involved in orchestrating responses to stress.
  • We are realizing these extend beyond influencing serotonin expression but actually demonstrates a potential to boost resilience to occasional stress and prevent its detrimental impact on overall mental and physical health."

How Technology Can Be a Game Changer in Mental Health Treatment and AI Is Leading the Way

Retrieved on: 
Wednesday, November 22, 2023
FDA, Psychotherapy, Health, DSM-IV codes, B2B, BDNF, News, Serum, USD, Mental health, Talkspace, Neurology, Diagnosis, Neuron, Q3, Couples therapy, Parkinson's disease, Depression, Alzheimer's disease, Artificial intelligence, Chatbot, Decision support system, Food, Conversation, Vitamin D, Firefly, Huntington's disease, Behavior, AI, Patient, Intelligence, Brain-derived neurotrophic factor, Survival, Sale, Research, Mental, My Little Pony, Ferhat Ozcep, Growth

Most medical experts agree we are in a global mental health crisis and it is only worsening.

Key Points: 
  • Most medical experts agree we are in a global mental health crisis and it is only worsening.
  • While some companies turn to traditional methods including pharmaceuticals to solve the growing problem, others are looking to revolutionize the way we treat mental health using technology, and AI is aiming to take the driver's seat.
  • Also using technology for mental health, Talkspace, a leading virtual behavioral healthcare company recently reported third quarter 2023 financial results.
  • As PanGenomic Health says – AI and other technology may become natural health's 'smart tech partner' of the future.

EnLiSense CCM To Advance IBD Care with Innovative Sweat Sensor Studies, Teams Up with Leading Clinicians

Retrieved on: 
Wednesday, October 4, 2023
Technology, Biotechnology, Health, Other Health, Professional Services, Research, Medical Devices, Software, General Health, Data Analytics, Genetics, Health Technology, Science, Data Management, Brain-derived neurotrophic factor, University, Crohn's & Colitis Foundation, GFAP, IBD, University of Texas at Austin, Melatonin, Interleukin 6, Biomarker, Glial fibrillary acidic protein, IL6, University of Glasgow, Crohn's disease, Patient, CRP, Physician, Conditional sentence, Inflammatory bowel disease, BDNF, Glucose, Skin, C-reactive protein, Pharmaceutical industry, Medical imaging, Cortisol, Calprotectin, CCM

Patients and clinicians are now actively being enrolled in these studies, marking a pivotal phase in EnLiSense's journey towards revolutionizing chronic disease management.

Key Points: 
  • Patients and clinicians are now actively being enrolled in these studies, marking a pivotal phase in EnLiSense's journey towards revolutionizing chronic disease management.
  • The IBD Aware system, a cornerstone of EnLiSense's innovative approach, continuously monitors key inflammatory biomarkers by gently resting on a patient’s skin sampling just nano-liters of passive sweat.
  • This non-invasive, wearable technology empowers both clinicians and patients with real-time data, facilitating personalized, data-driven, proactive management of chronic diseases like IBD.
  • Dr. Sriram Muthukumar, CEO of EnLiSense CCM, reflects on the early findings, stating, "The initial validation data is indeed very encouraging.

People with Parkinson's may benefit from cardio, weight training and yoga – here's what you need to know

Retrieved on: 
Monday, July 10, 2023
Exercise, Yoga, YouTube, Neuron, Delayed onset muscle soreness, Brain-derived neurotrophic factor, Tremor, FNDC5, Overalls, Survival, Clinical trial, Joint stiffness, Quality of life, B cell, Brain, Swimming, Falls, Movement, Pain, Gardening, Walking, Cooking, Risk, Research, Disease, Dietary supplement, Poultry farming, Vaccine

This was highlighted in a recent video posted by British fitness influencer Joe Wicks on his YouTube channel.

Key Points: 
  • This was highlighted in a recent video posted by British fitness influencer Joe Wicks on his YouTube channel.
  • In the video, Wicks guides viewers through exercises they can do if they have Parkinson’s disease – and explains why it’s important to keep moving.
  • There have been several scientific studies exploring the impact of different types of exercise on people with Parkinson’s disease.
  • On the whole, most types of exercise have been shown to have a positive effect on people with Parkinson’s – improving quality of life and physical symptoms.
  • One clinical trial, for instance, found that high-intensity exercise may reduce the severity of motor symptoms in people recently diagnosed with Parkinson’s disease.

Tailored workouts

    • It’s also important that people with Parkinson’s consult their GP when putting together an exercise regime.
    • This is to avoid risk of pain, injury or falls by determining which exercises suit each person.
    • And, these activities may be easier to incorporate into your daily routine than a gym workout.

Exercise can help prevent and treat mental health problems, and taking it outside adds another boost to those benefits

Retrieved on: 
Tuesday, May 2, 2023
Exercise, Cannabinoid, Learning, Brain-derived neurotrophic factor, Depression, Disease, Schizophrenia, Disability, Anxiety, Canadian Mental Health Association, Parks Canada, Mental health, DSM-IV codes, Endorphins, Research, Brain, Penn Entertainment, Meta-analysis, Personality, Hormone, Pain, Tree, Running, Death, Walking, Patient, Nature, Happiness, United Kingdom, Growth, BDNF, Memory, Hippocampus, Nursing, Poultry farming, Dietary supplement, Health, Mental

The Canadian Mental Health Association estimates that by the age of 40, about half of people will either have had a mental illness or will currently be dealing with one.

Key Points: 
  • The Canadian Mental Health Association estimates that by the age of 40, about half of people will either have had a mental illness or will currently be dealing with one.
  • However, research has shown the importance of exercise in not only preventing mental illness, but also treating it.
  • Of these, anxiety and depression are the most common, with depression being the leading cause of disability worldwide.

Exercise can make you happy

    • Exercise and activity have long been known to improve mood.
    • And the greatest benefits occurred in those people who exercised 45 minutes or more for three or more days per week.
    • Over time, regular exercise can result in less likelihood for getting depression and anxiety.

Exercise as treatment for mental illness

    • Numerous studies indicate exercise as an effective treatment for people with existing depression and other mental illnesses.
    • While exercise is beneficial at all intensity levels, it appears higher intensity exercise may be more effective than low intensity.

How exercise works to improve mental well-being

    • Exercise may improve mental well-being due to the release of hormones and brain function.
    • Exercise can increase BDNF levels in people with depression, as well as increase hippocampus volume.

Take it outside

    • It is associated with greater chances for mental illness, but can be reduced with a walk through a natural environment.
    • This follows similar programs in many other countries such as New Zealand, Japan, the United States and the United Kingdom.
    • But for others, exercising in nature is a simple and cost-saving activity to maintain your mental health and treat mental illnesses.
    • Scott Lear writes a biweekly blog Become Your Healthiest You and co-hosts a monthly podcast How to Health.

Neuro20 Technologies Announces FDA Clearance of the Neuro20 PRO System for Treatment of Neuromuscular Injury and Disease

Retrieved on: 
Thursday, March 2, 2023
FDA, Rehabilitation, Electrical muscle stimulation, Patient, PEMS, Relaxation, Injury, Software, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Muscle atrophy, Suit, Brain-derived neurotrophic factor, Disease, Gene expression, Food, Movement, Medical device, BDNF

TAMPA, Fla., March 2, 2023 /PRNewswire/ -- Neuro20 Technologies Corp, a wearable medical device manufacturing company specializing in the development of next-generation wireless wearable textiles to treat neuromuscular injuries and disease while enhancing human performance outcomes, today announced that the U.S. Food and Drug Administration (FDA) has cleared the company's 510(k) pre-market approval application for its Neuro20 PRO System.

Key Points: 
  • I personally use the Neuro20 PRO System to re-acquire and maintain optimal movement patterns due to injuries sustained over a lifetime of athletic competitions."
  • The Neuro20 PRO System's Suit has large-contoured electrodes to cover maximum motor neuron activation, distinguishing it from current electrical muscle stimulation systems on the market.
  • "FDA clearance of our Neuro20 PRO System to treat neuromuscular injury and disease is a significant milestone for Neuro20 Technologies as we prepare to educate the market about the benefits of this technological advancement," said Dennis M. Schmitt, Chief Executive Officer of Neuro20 Technologies.
  • The Neuro20 PRO system is the reconceptualization of electrical muscle stimulation to make it more efficient for both provider and patient.

PLT Introduces Novel, Botanical Cognitive Performance Ingredient with a Broad Set of Benefits

Retrieved on: 
Monday, February 27, 2023
Recognition memory, Female, Athens insomnia scale, Overalls, Learning, Function (mathematics), Ellagic acid, Produce traceability, Episodic, Long-term memory, Amyrin, Brain, BDNF, Episodic memory, Innovation, Memory, Gallic acid, Brain-derived neurotrophic factor, Rate, Male, Short-term memory, PLT, PAI, Concentration, Learning rate, Theory, Working memory, Cambridge Neuropsychological Test Automated Battery, Ageing, Nursing, Pharmaceutical industry, CANTAB, Boswellia, RD, Recognition

MORRISTOWN, N.J., Feb. 27, 2023 /PRNewswire/ -- PLT Health Solutions, Inc is launching a novel ingredient to support a broad range of cognitive performance abilities. Called Nutricog® Cognitive Performance Complex, it is a patented combination of Haritaki (Terminalia chebula) and Boswellia (Boswellia serrata) — standardized to gallic acid, ellagic acid and amyrins. In a randomized, double-blind, placebo-controlled clinical trial, users of Nutricog demonstrated significant improvements compared to placebo across multiple cognitive domains, including learning, memory, sustained attention, working memory and executive function, where increases in cognitive speed were seen concurrently with improvements in accuracy while multitasking. The earliest clinically significant benefits (memory and focus) for Nutricog were shown to start at just 15 days after commencing use. PLT is introducing Nutricog at Natural Products Expo West in March and at Vitafoods Europe in May.

Key Points: 
  • Called Nutricog® Cognitive Performance Complex, it is a patented combination of Haritaki (Terminalia chebula) and Boswellia (Boswellia serrata) — standardized to gallic acid, ellagic acid and amyrins.
  • According to Seth Flowerman, President & CEO of PLT Health Solutions, the new ingredient was developed in response to consumer interest in maximizing cognitive support as a quality-of-life issue.
  • "Today, we are seeing rapidly increasing interest in cognitive support for a broad range of lifestyle goals.
  • At PLT, we're very excited to be introducing Nutricog to the market after more than five years in development.

Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study

Retrieved on: 
Tuesday, January 17, 2023
Infarction, Edmund, AGN, Spirit, Brain, Stroke, Brain-derived neurotrophic factor, Division, CSE, Trial of the century, Pharmacokinetics, DMT, Safety, Imperial College London, Department of Medicine – University of Pamplona, Rehabilitation, Neuroprotection, Calendar, Hammersmith Hospital, Diagnosis, Patient, Growth hacking, Neuroplasticity, BDNF, Neuroimmunology, Pharmaceutical industry

“I am delighted that Algernon NeuroScience has begun their Phase 1 DMT study,” said Dr. Rick Strassman, author of DMT: The Spirit Molecule and Algernon consultant.

Key Points: 
  • “I am delighted that Algernon NeuroScience has begun their Phase 1 DMT study,” said Dr. Rick Strassman, author of DMT: The Spirit Molecule and Algernon consultant.
  • The resulting data generated will help the Company to plan both a Phase 2 acute stroke and rehabilitation study more effectively.
  • “This Phase 1 study is an important milestone as we advance our investigation of DMT for the treatment of stroke,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.
  • “We anticipate receiving data from this study in Q3 2023, and potentially beginning Phase 2 studies in stroke patients by the end of the calendar year.”

Algernon Pharmaceuticals Screens First Subject in Phase 1 DMT Human Stroke Study

Retrieved on: 
Wednesday, November 16, 2022
Stroke, N,N-Dimethyltryptamine, CHDR, Pharmacokinetics, Patient, LSD, Amazon, Brain-derived neurotrophic factor, Drug development, Niacin, Rehabilitation, Chronic kidney disease, AGN, Chronic cough, Psilocybin, Ketamine, CSE, Human, IPF, Animal, DMT, Trial of the century, Safety, Brain, Constraint-induced movement therapy, Pharmaceutical industry, Medical imaging

The company plans to open enrollment shortly and dose the first subject of the study in December 2022.

Key Points: 
  • The company plans to open enrollment shortly and dose the first subject of the study in December 2022.
  • We are very excited to be initiating our DMT clinical stroke research program with our Phase 1 study at CHDR in the Netherlands, said Christopher J. Moreau CEO of Algernon Pharmaceuticals.
  • Algernon has filed patents for DMT pamoate and nicotinate (novel salt forms of DMT) in addition to formulation, dosage and method of use claims for ischemic stroke.
  • Algernon has active research programs for IPF with chronic cough, chronic kidney disease, and a psychedelic program investigating a proprietary form of DMT for stroke.